ARTELO BIOSCIENCES Business Summary

Artelo Biosciences, Inc. (ARTL) is a clinical-stage biopharmaceutical company that operates on a research and development business model, generating value through the discovery, licensing, and clinical advancement of proprietary therapeutics targeting lipid-signaling pathways. The company is currently pre-revenue, with its financial strategy centered on achieving clinical milestones to attract licensing agreements, milestone payments, or future commercialization opportunities. Its primary business segments are defined by its lead drug candidates: ART27.13, a peripheral G-protein coupled receptor agonist for cancer-associated anorexia; ART26.12, a fatty acid binding protein 5 (FABP5) inhibitor for pain and oncology; and ART12.11, a patented cannabidiol cocrystal. Direct competitors include Soligenix, CASI Pharmaceuticals, Akari Therapeutics, and Octavian Therapeutics; Artelo distinguishes itself by focusing on the endocannabinoid system’s therapeutic potential while utilizing synthetic small molecules to avoid the psychotropic effects of plant-derived cannabinoids. The leadership team is anchored by President and CEO Gregory D. Gorgas, who has led the company since its 2017 transition and brings over 30 years of experience from Biogen, Chiron, and IDEC Pharmaceuticals. Key executives include Chief Financial Officer Mark Spring, a veteran with 30 years of life sciences experience at MedImmune and Baxter, and Chief Scientific Officer Dr. Andrew Yates, who previously held executive roles at AstraZeneca for a decade. Clinical development is managed by Chief Medical Officer Dr. Steven D. Reich, an oncologist with over 40 years of experience in Phase I-IV trials. The company’s board is chaired by Connie Matsui, a former Executive Vice President at Biogen Idec, and notable institutional investors include UBS Asset Management, The Vanguard Group, and Geode Capital Management.